Cannabinoids affect the brain's glial cells in ways that may be relevant to schizophrenia
A review found that glial cells (the brain's support cells) express cannabinoid receptors and are altered in schizophrenia, suggesting that cannabinoid drugs could potentially modulate glial dysfunction involved in the disorder.
Quick Facts
What This Study Found
This review examined the intersection of two lines of research: glial cell dysfunction in schizophrenia and the endocannabinoid system's effects on glial cells.
Glial cells, which include oligodendrocytes, microglia, and astrocytes, perform essential functions in the brain including myelination, metabolic support, and immune response. Impairments in these cells disrupt neuronal communication and homeostasis in ways implicated in schizophrenia.
The endocannabinoid system has been linked to schizophrenia pathophysiology through its modulation of dopaminergic and glutamatergic neurotransmission, both associated with positive, negative, and cognitive symptoms.
Critically, glial cells express cannabinoid receptors and synthesize endocannabinoids. Cannabinoid drugs affect glial cell functions that are specifically disrupted in schizophrenia, suggesting these cells could be a pharmacological target for treatment.
Key Numbers
Three main glial cell types affected: oligodendrocytes, microglia, astrocytes. Endocannabinoid system modulates both dopaminergic and glutamatergic transmission implicated in schizophrenia.
How They Did This
Narrative review synthesizing published research on glial cell changes in schizophrenia, endocannabinoid system involvement in the disorder, and the effects of cannabinoids on glial cell function.
Why This Research Matters
Schizophrenia treatment has focused primarily on neurotransmitter systems. If glial cells represent an overlooked target, and cannabinoid drugs can modulate their function, this opens a potentially new therapeutic approach for a disorder that remains difficult to treat.
The Bigger Picture
This review represents an emerging research direction that looks beyond neurons to the brain's support cells. The connection between the endocannabinoid system and glial function in schizophrenia could eventually inform new treatment strategies, though the research is still in early stages.
What This Study Doesn't Tell Us
This is a narrative review synthesizing existing research rather than reporting new data. Much of the evidence connecting cannabinoids, glial cells, and schizophrenia comes from preclinical studies. The complexity of schizophrenia means that targeting one system may not translate to clinical benefit.
Questions This Raises
- ?Could cannabinoid-based drugs that specifically target glial cells reduce schizophrenia symptoms without the psychoactive effects associated with THC?
- ?Which glial cell type is most relevant to each symptom domain of schizophrenia?
Trust & Context
- Key Stat:
- Glial cells express cannabinoid receptors and are altered in schizophrenia
- Evidence Grade:
- This is a narrative review synthesizing preclinical and clinical observations, providing preliminary theoretical evidence rather than direct clinical findings.
- Study Age:
- Published in 2018. Research on glial involvement in psychiatric disorders has continued to develop.
- Original Title:
- Cannabinoids and glial cells: possible mechanism to understand schizophrenia.
- Published In:
- European archives of psychiatry and clinical neuroscience, 268(7), 727-737 (2018)
- Authors:
- de Almeida, Valéria, Martins-de-Souza, Daniel
- Database ID:
- RTHC-01637
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are glial cells?
Glial cells are the brain's support cells, including oligodendrocytes (which insulate nerve fibers), microglia (immune response), and astrocytes (metabolic support). They make up roughly half of the brain's cells.
Does this mean cannabis causes or treats schizophrenia?
Neither. The review identifies a biological connection between the endocannabinoid system and glial cell dysfunction seen in schizophrenia, suggesting a potential future drug target, not a direct causal or therapeutic relationship with cannabis itself.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01637APA
de Almeida, Valéria; Martins-de-Souza, Daniel. (2018). Cannabinoids and glial cells: possible mechanism to understand schizophrenia.. European archives of psychiatry and clinical neuroscience, 268(7), 727-737. https://doi.org/10.1007/s00406-018-0874-6
MLA
de Almeida, Valéria, et al. "Cannabinoids and glial cells: possible mechanism to understand schizophrenia.." European archives of psychiatry and clinical neuroscience, 2018. https://doi.org/10.1007/s00406-018-0874-6
RethinkTHC
RethinkTHC Research Database. "Cannabinoids and glial cells: possible mechanism to understa..." RTHC-01637. Retrieved from https://rethinkthc.com/research/de-2018-cannabinoids-and-glial-cells
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.